Best Practices in Drug and Biological Product Postmarket Safety Surveillance for Food and Drug Administration Staff; Draft Document; Reopening of Comment Period

Короткий зміст

The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the notice entitled "Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff; Draft Document; Availability; Establishment of Public Docket; Request for Comments" that appeared in the Federal Register of November 7, 2019. The Agency is taking this action to allow interested persons additional time to submit comments.